Primary Pericardial Mesothelioma: A Population-Based Propensity Score-Matched Analysis

Brydges, Hilliard T.; Yin, Kanhua; Balasubramaniyan, Ramkumar; Lawrence, Kyle W.; Luo, Rongkui; Karlson, Karl J.; McAneny, David; Edwards, Niloo M.; Reardon, Michael J.; Dobrilovic, Nikola

doi:10.1053/j.semtcvs.2021.07.020

Cited by 10 publications

(16 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Studies have shown that a combination of doxorubicin, vincristine, and cyclophosphamide reduces tumour progression prolonging survival up to 17.5 months. 11 Similarly, a study conducted by Kim et al reported that combining cisplatin, gemcitabine, and vinorelbine in 4 cycles enabled the patient to remain disease-free for 24 months after completion of chemotherapy. 2 Newer therapies for PPMM including anti-angiogenesis drugs, photodynamic therapy, gene therapy, biologic response modifiers, and more targeted chemotherapy regimens are currently undergoing clinical trials.…”

Section: Discussionmentioning

confidence: 96%

See 1 more Smart Citation

Diagnostic challenges of pericardial mesothelioma: A case report and review of literature

Thanalingam

Sinha

et al. 2022

Preprint

View full text Add to dashboard Cite

Primary pericardial malignant mesothelioma (PPMM) is a rare malignancy arising from the serous mesothelial lining of the pericardium. These neoplasms are aggressive, pose diagnostic difficulties, and have a poor prognosis. The median survival is less than six months. Presenting symptoms are non-specific and include fatigue, dyspnea, and low-grade fever. Given the nature of presenting symptoms, it is imperative that appropriate imaging, tissue sampling, and histological analysis are undertaken to establish a clinical diagnosis. In cases of localised disease, surgical resection remains the primary treatment. In advanced disease, chemotherapy or palliative procedures may be beneficial. We describe two cases of PPMM and provide an update and guidance on the contemporaneous management of this challenging condition.

show abstract

Section: Discussionmentioning

confidence: 96%

“…These therapies provide hope for better treatment options in the future. 2,6,11 Presently it appears multimodal therapy confers the most notable median survival rate in patients diagnosed with PPMM.…”

Section: Discussionmentioning

confidence: 99%

Diagnostic challenges of pericardial mesothelioma: A case report and review of literature

Thanalingam

Sinha

et al. 2022

Preprint

View full text Add to dashboard Cite

show abstract

“…Studies have shown that a combination of doxorubicin, vincristine, and cyclophosphamide reduces tumour progression prolonging survival up to 17.5 months. 11 Similarly, a Page 5/9 study conducted by Kim et al reported that combining cisplatin, gemcitabine, and vinorelbine in 4 cycles enabled the patient to remain disease-free for 24 months after completion of chemotherapy. 2 Newer therapies for PPMM including anti-angiogenesis drugs, photodynamic therapy, gene therapy, biologic response modi ers, and more targeted chemotherapy regimens are currently undergoing clinical trials.…”

Section: Discussionmentioning

confidence: 98%

Section: Discussionmentioning

confidence: 99%

Diagnostic challenges of pericardial mesothelioma: A case report and review of literature

Kejriwal

Thanalingam

Sinha

et al. 2022

Preprint

View full text Add to dashboard Cite

Background Primary pericardial malignant mesothelioma (PPMM) is a rare malignancy arising from the serous mesothelial lining of the pericardium. These neoplasms are aggressive in nature, pose diagnostic difficulties, have a poor prognosis, and have a median survival of fewer than six months. Case presentation The first case involves a 75-year-old woman who presented with progressively worsening dyspnoea, unintentional weight loss, intermittent fevers, and chest pain. A chest computed tomography (CT) scan revealed thickened pericardium and two large pericardial masses anterior to the right ventricle. The second case involves a 77-year-old man who presented with progressively worsening dyspnoea, fatigue, and decreased exercise tolerance. A chest CT scan revealed an irregular soft tissue mass posterior to the left atrium with bilateral pleural effusions and an absence of mediastinal lymphadenopathy. Histopathological analysis of both cases revealed malignant pericardial mesothelioma with homozygous deletion of CDKN2A. Due to extensive disease, both patients were referred to medical oncology for palliative chemotherapy. Both patients died two months following receiving a formal diagnosis of PPMM. Conclusion PPMM remains a rare and poorly understood malignancy of undetermined aetiology. We describe two cases of PPMM and provide an update and guidance on the contemporaneous management of this challenging condition.

show abstract

“…2 The disease predominantly affects white patients (75.6%), with a varying male-to-female ratio ranging from 1:1 to 3:1. [1][2][3][4] The role of asbestos exposure in the pathogenesis of PM is unclear because of discordant results among studies. In a study by Marinaccio and colleagues evaluating the risk of PM related to asbestos exposure in a cohort of 58 patients identified in the ReNaM during the period 1993 to 2015, 62% of patients had definite, probable, or possible asbestos exposure in an occupational setting, suggesting a significant association between asbestos exposure and the risk of PM (odds ratio: 3.68, 95% CI: 1.85-7.31).…”

Section: Demographicsmentioning

confidence: 99%

Pericardial Mesotheliomas

Arrossi¹

2023

Advances in Anatomic Pathology

View full text Add to dashboard Cite

Primary pericardial mesothelioma (PM) is a rare tumor arising from the mesothelial cells of the pericardium. It has an incidence of <0.05% and comprises <2% of all mesotheliomas; however, it is the most common primary malignancy of the pericardium. PM should be distinguished from secondary involvement by the spread of pleural mesothelioma or metastases, which are more common. Although data are controversial, the association between asbestos exposure and PM is less documented than that with other mesotheliomas. Late clinical presentation is common. Symptoms may be nonspecific but are usually related to pericardial constriction or cardiac tamponade, and diagnosis can be challenging usually requiring multiple imaging modalities. Echocardiography, computed tomography, and cardiac magnetic resonance demonstrate heterogeneously enhancing thickened pericardium, usually encasing the heart, with findings of constrictive physiology. Tissue sampling is essential for diagnosis. Histologically, similar to mesotheliomas elsewhere in the body, PM is classified as epithelioid, sarcomatoid, or biphasic, with the biphasic type being the most common. Combined with morphologic assessment, the use of immunohistochemistry and other ancillary studies is helpful for distinguishing mesotheliomas from benign proliferative processes and other neoplastic processes. The prognosis of PM is poor with about 22% 1-year survival. Unfortunately, the rarity of PM poses limitations for comprehensive and prospective studies to gain further insight into the pathobiology, diagnosis, and treatment of PM.

show abstract

Primary Pericardial Mesothelioma: A Population-Based Propensity Score-Matched Analysis

Cited by 10 publications

References 23 publications

Diagnostic challenges of pericardial mesothelioma: A case report and review of literature

Diagnostic challenges of pericardial mesothelioma: A case report and review of literature

Diagnostic challenges of pericardial mesothelioma: A case report and review of literature

Pericardial Mesotheliomas

Contact Info

Product

Resources

About